Therapy Targeting the Interleukin-3 Receptor (IL3R) for Patients With Relapsed or Refractory and Elderly or Poor-Risk Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome With DTIL3 (IND 11314): a Phase I/II Clinical Trial.

Trial Profile

Therapy Targeting the Interleukin-3 Receptor (IL3R) for Patients With Relapsed or Refractory and Elderly or Poor-Risk Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome With DTIL3 (IND 11314): a Phase I/II Clinical Trial.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Sep 2016

At a glance

  • Drugs SL 401 (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Sep 2016 Status changed from completed to active, no longer recruiting.
    • 02 Sep 2016 Planned End Date changed from 1 May 2016 to 1 Oct 2018.
    • 04 Nov 2014 Trial staus is completed, according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top